ROIV logo
Roivant Sciences Ltd.(ROIV)
$36.48—

Russell 2000 below the 50-day average

Overview →

ROIV News

About

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Matthew Gline
Country
UK
Leadership (12)
Frank TortiPresident & Vant Chair
Huafeng XuChief Technology Officer
Mayukh SukhatmePresident, Chief Investment Officer & Director
Matthew GlineChief Executive Officer & Director
Richard PulikChief Financial Officer
Sam KaplanGeneral Counsel
Deya CorzoChief Medical Officer-In-Residence
Eric VenkerPresident & Chief Executive Officer of Immunovant
Alex GasnerExecutive Vice President of Roivant Health
Ian RosenblumChief Information Officer
Jennifer HumesChief Accounting Officer
Kelly GraffHead of People
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.